We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
EnClear Therapies has spun-out from QurAlis Corporation, a biotech company focused on developing precision therapeutics for ALS and other neurological diseases. EnClear’s mission is to halt the progression of ....
QurAlis announced the addition of biotech investors MP Healthcare Venture Management (MPH), Amgen Ventures, and Alexandria Venture Investments, who have joined to cure Amyotrophic Lateral Sclerosis (ALS)